Positron emission tomography (PET) constitutes a functional imaging technique that is
harnessed to probe biological processes in vivo. PET imaging has been used to diagnose …

Simple Summary Antibody-drug conjugates (ADC) are a rapidly expanding class of anti-
cancer drugs, with twelve agents in current clinical use. Despite recent successes, many …

Simple Summary Antibody–drug conjugates (ADC) have shown remarkable therapeutic
activity in a wide range of hematologic and solid tumors. Herein, we discuss the …

Antibody–drug conjugates (ADC) are one of the fastest growing anticancer drugs. This
approach comprises a mAb conjugated to the cytotoxic payload via a chemical linker that …

Antibody–drug conjugates (ADCs) are immunoconjugates comprised of a monoclonal
antibody tethered to a cytotoxic drug (known as the payload) via a chemical linker. The ADC …

Antibody-Drug Conjugates (ADCs) represent an innovative class of potent anti-cancer
compounds that are widely used in the treatment of hematologic malignancies and solid …

Antibody–Drug Conjugates (ADCs) are now established as a major class of therapeutics for
the clinical treatment of cancer. The properties of the linker between the antibody and the …

Antibody-drug conjugates (ADCs) are one of fastest growing classes of oncology drugs in
modern drug development. By harnessing the powers of both cytotoxic chemotherapy and …

Antibody–drug conjugates (ADCs) are a family of targeted therapeutic agents for the
treatment of cancer. ADC development is a rapidly expanding field of research, with over 80 …

The primary purpose of ADCs is to increase the efficacy of anticancer medications by
minimizing systemic drug distribution and targeting specific cells. Antibody conjugates …